Testosterone Formulations: Titration and Tapering Algorithms

What Is the Testosterone Formulations Drug Class?

Testosterone formulations are exogenous androgen preparations approved by the FDA for treatment of hypogonadism in males with confirmed low serum testosterone. The class includes injectable esters, transdermal gels and solutions, transdermal patches, buccal tablets, intranasal gels, and subcutaneous pellets. The prototype is testosterone cypionate, an oily ester injection with a half-life of approximately 8 days that has been available since 1951 [1].

The Endocrine Society's 2018 Clinical Practice Guideline defines male hypogonadism as "a clinical syndrome that results from failure of the testis to produce physiological concentrations of testosterone," requiring both symptoms and a confirmed morning serum testosterone below 300 ng/dL on two separate occasions [2].

Why Formulation Choice Drives Titration Strategy

Each delivery vehicle produces a different pharmacokinetic profile. Injectables create peak-and-trough swings. Gels produce relatively stable daily levels. Pellets release slowly over 3 to 6 months. These differences are not cosmetic. They determine how often you draw labs, when you draw them, and by how much you adjust the dose.

A prescriber who applies injection titration logic to a gel will systematically over-treat or under-treat. The algorithm must match the formulation.

Confirmed Diagnosis Before Starting

The FDA label for testosterone products specifies use only in men with documented hypogonadism [3]. Before initiating any formulation, obtain two morning testosterone draws (before 10:00 AM) on separate days. Confirm LH and FSH to distinguish primary from secondary hypogonadism. Rule out hyperprolactinemia, hemochromatosis, and pituitary pathology in secondary cases before attributing low testosterone to idiopathic hypogonadotropic hypogonadism [2].

Injectable Testosterone Esters: Cypionate and Enanthate

Injectable esters are the most prescribed testosterone formulations in the United States. Testosterone cypionate (200 mg/mL) and testosterone enanthate (200 mg/mL) are clinically interchangeable, with half-lives of approximately 8 and 4.5 days, respectively [4]. Both are administered intramuscularly or subcutaneously.

Starting Dose and Titration Schedule

The Endocrine Society guideline recommends starting testosterone cypionate or enanthate at 75 to 100 mg weekly, or 150 to 200 mg every two weeks [2]. Weekly dosing is preferred because biweekly dosing produces wider peak-to-trough swings, which correlate with mood variability and erythrocytosis risk.

Standard titration protocol:

| Week | Action | Lab Timing | |------|--------|------------| | 0 | Start 100 mg/week IM or SQ | Baseline testosterone, CBC, PSA | | 6 | Check trough (day of injection, pre-dose) | Total T, hematocrit | | 6 to 8 | Adjust dose by 10 to 20 mg/week if trough <400 ng/dL |, | | 12 | Re-check trough | Total T, free T, hematocrit, PSA | | 12 to 14 | Finalize maintenance dose | Full metabolic panel |

Target trough for most men: 400 to 700 ng/dL. Avoid sustained troughs above 900 ng/dL on weekly dosing, as this increases erythrocytosis risk [5].

Dose Adjustment Rules

Increase by 20 mg/week if trough is below 400 ng/dL and the patient reports persistent symptoms. Hold or reduce by 20 mg/week if trough exceeds 800 ng/dL or hematocrit rises above 54% [2]. The FDA's 2014 Drug Safety Communication flagged cardiovascular risk signals in men with non-hypogonadal testosterone use, reinforcing the need to maintain levels within physiologic range [3].

Do not adjust dose more frequently than every 6 weeks. Testosterone cypionate requires approximately 5 half-lives (40 days) to reach steady state after a dose change [4].

Subcutaneous vs. Intramuscular Delivery

Subcutaneous injection of testosterone cypionate at 50 to 100 mg/week produces comparable serum levels to intramuscular delivery with a modestly lower peak, which may reduce erythrocytosis. A 2017 retrospective analysis (N=394) published in the Journal of Urology found that SQ testosterone produced mean trough levels of 480 ng/dL, comparable to IM delivery, with a lower rate of hematocrit elevation above 50% (13.8% vs. 17.8%) [6].

Transdermal Gels and Solutions

Transdermal gels (AndroGel 1%, AndroGel 1.62%, Testim, Vogelxo) and solutions (Axiron) deliver testosterone through the skin with a half-life approximating the natural diurnal rhythm of roughly 24 hours, producing steadier serum levels than injectables.

Titration Protocol for Gels

Draw serum testosterone 2 to 8 hours after application, ideally at steady state (after 14 days of consistent use) [3]. Do not draw levels on the day of initiation or after a missed application.

Starting dose for AndroGel 1.62%: 40.5 mg/day (2 pump actuations). Titration thresholds:

• If serum testosterone is below 400 ng/dL at week 2: increase to 60.75 mg/day (3 pumps).
• If serum testosterone is above 750 ng/dL: decrease to 20.25 mg/day (1 pump).
• Recheck at day 28 to 42 after any dose change [3].

Transfer Risk and Monitoring

Gel transfer to female partners or children is a documented safety concern. The FDA label mandates patient counseling on application site coverage and hand washing [3]. Skin-to-skin transfer studies show measurable testosterone elevation in female partners after 15 minutes of direct contact with an uncovered application site. Prescribers should document this counseling in every chart.

Transdermal Patches

The Androderm patch (2 mg/day and 4 mg/day) delivers testosterone continuously over 24 hours. Applied nightly to the back, abdomen, upper arm, or thigh, it produces serum levels that mimic circadian testosterone rhythm [7].

Patch Titration

Start with 4 mg/day. Check serum testosterone after 14 days, in the morning after patch application (2 to 4 hours post-application). Target 400 to 700 ng/dL. If below 400: increase to two 4 mg patches. If above 700: reduce to 2 mg/day patch. Skin irritation affects 12 to 37% of patients and is the primary reason for discontinuation [7].

Intranasal Testosterone (Natesto)

Natesto 4.5% gel delivers 11 mg per nostril per actuation, dosed three times daily. It produces rapid absorption with a half-life of approximately 10 to 100 minutes, returning to baseline within 12 hours of last dose [8].

Titration for Natesto

The short half-life makes Natesto the formulation least likely to suppress the HPG axis chronically, preserving some LH and FSH secretion in many men [8]. This makes it a preferred option when fertility preservation matters.

Check serum testosterone approximately 4 to 6 hours after the morning dose at steady state (day 7). Target 300 to 1000 ng/dL on a mid-dose measurement. The prescribing information supports a range of 1 to 3 doses daily; however, most men require TID dosing to sustain adequate levels [8].

Testosterone Pellets (Testopel)

Subcutaneous pellets (75 mg each) are implanted in the lateral hip or flank under local anesthesia, typically every 3 to 6 months. Starting dose: 150 to 450 mg (2 to 6 pellets), based on weight, activity level, and prior testosterone levels.

Pellet Titration Challenges

Pellets cannot be removed or dose-adjusted after insertion. Titration is retrospective. Draw serum testosterone at week 4 (peak) and week 12 to 16 (trough) to calibrate the next insertion dose. If the week-4 peak exceeds 1100 ng/dL, reduce by one pellet next cycle. If the week-12 trough falls below 400 ng/dL, add one pellet next cycle [9].

Pellet extrusion occurs in approximately 3.3% of insertions [9]. Document insertion site, lot number, and pellet count in the chart for every procedure.

Buccal Testosterone (Striant)

Striant 30 mg buccal tablets are applied to the gum above the incisor twice daily, releasing testosterone over 12 hours. This route avoids first-pass hepatic metabolism. Serum testosterone is checked 4 to 12 hours after application. Target range is 300 to 1000 ng/dL. Gum irritation, bitter taste, and twice-daily adherence demands limit uptake [10].

Titration Across Formulations: A Unifying Framework

All formulations share a three-phase titration logic, regardless of delivery route:

Phase 1 (Initiation, weeks 0 to 6): Start at the lower end of the approved dose range. Draw baseline CBC, PSA, and testosterone. Set patient expectations: symptom response lags biochemical normalization by 3 to 6 weeks.

Phase 2 (Optimization, weeks 6 to 16): Adjust dose based on trough (injectables) or post-absorption peak (gels, intranasal, buccal). Adjust by the smallest unit the formulation permits. Do not adjust more than once per pharmacokinetic steady state. Confirm symptoms are improving and hematocrit remains below 54%.

Phase 3 (Maintenance, beyond week 16): Check testosterone and hematocrit every 6 to 12 months. Recheck PSA at 3 to 6 months after initiation, then per AUA guidelines [11]. Adjust only if levels drift or symptoms change.

The Endocrine Society specifies that once a stable dose is established, monitoring can occur annually in the absence of dose changes, erythrocytosis, or new symptoms [2].

Tapering Algorithms: When and How to Reduce Testosterone

Tapering testosterone is not a routine step at the end of treatment. It is indicated in three clinical situations: (1) erythrocytosis with hematocrit persistently above 54%, (2) desire to recover fertility, and (3) patient-initiated discontinuation after discussing HPG axis suppression.

Tapering for Erythrocytosis

Testosterone-induced erythrocytosis is the most common adverse effect requiring dose reduction, occurring in 3 to 18% of treated men depending on formulation and dose [5]. The Endocrine Society recommends stopping testosterone or reducing dose when hematocrit exceeds 54%, then rechecking hematocrit after 4 weeks [2].

For cypionate, reduce weekly dose by 25 to 30% and recheck hematocrit at 6 weeks. If hematocrit normalizes to below 52%, resume at the reduced dose. Phlebotomy is an alternative for men whose hypogonadism symptoms return during dose reduction.

Tapering for Fertility Recovery

Exogenous testosterone suppresses LH and FSH, reducing intratesticular testosterone and impairing spermatogenesis [12]. Men who wish to conceive after TRT should stop testosterone entirely. Do not taper slowly. Abrupt cessation followed by clomiphene 25 to 50 mg/day or human chorionic gonadotropin (hCG) 1500 to 3000 IU three times weekly accelerates HPG axis recovery [12].

A 2013 prospective study (N=49) by Lipshultz et al. Found that HPG axis recovery after TRT cessation required a median of 3.7 months with hCG support vs. 7.3 months with watchful waiting (P<0.01) [12]. Recovery of sperm counts to greater than 10 million/mL required a median of 6 months with combination hCG plus FSH in hypogonadotropic cases.

Tapering for Patient-Initiated Discontinuation

Some patients wish to stop TRT after a trial period. Low testosterone symptoms are likely to return. This is not a safety-driven taper; it is an informed discontinuation. Reduce dose by 25% every 4 weeks over a 12 to 16-week window to blunt symptomatic hypogonadism during the transition. Confirm that the patient understands serum testosterone may fall below pre-treatment baseline for 8 to 16 weeks post-cessation while the HPG axis recovers.

Monitor LH and FSH every 6 to 8 weeks after stopping. If LH and FSH remain suppressed beyond 6 months, secondary hypogonadism may be unmasked, and the patient may require ongoing therapy.

Hematocrit and Cardiovascular Monitoring During Titration

The FDA's 2015 label update required all testosterone products to carry a warning about potential cardiovascular risk [3]. A 2010 randomized trial (N=209) in frail older men (Basaria et al., NEJM) was stopped early after a statistically significant increase in cardiovascular events in the testosterone arm (23 events vs. 5, P<0.001) [13]. That population had high baseline cardiovascular risk, but the trial established the framework for careful monitoring.

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone replacement in men with hypogonadism and elevated cardiovascular risk did not significantly increase major adverse cardiovascular events (MACE) over a mean follow-up of 22 months (7.0% testosterone vs. 7.3% placebo; HR 0.96, 95% CI 0.78 to 1.17) [14]. This data has been used to partially reassure prescribers, though the study was powered for non-inferiority, not superiority.

Hematocrit above 54% independently increases thrombotic risk. Check hematocrit at baseline, at 3 to 6 months, and annually thereafter [2].

PSA Monitoring During Titration

Testosterone does not cause prostate cancer, but it may accelerate growth of subclinical disease. The Endocrine Society guideline states: "We suggest measuring PSA levels and performing a digital rectal examination before starting testosterone therapy in men over 40 years of age who are at increased risk of prostate cancer" [2].

Recheck PSA at 3 to 6 months after starting therapy. A confirmed PSA rise of greater than 1.4 ng/mL above baseline within 12 months, or any single PSA above 4 ng/mL, warrants urology referral before continuing or escalating the testosterone dose [2].

Drug Interactions Relevant to Titration

Testosterone is a substrate and mild inducer of CYP3A4. Anticoagulant dose requirements change with testosterone initiation. A prospective study (N=38) found that testosterone co-administration with warfarin reduced warfarin requirements by a mean of 22% [15]. Check INR 2 to 4 weeks after starting testosterone in any patient on warfarin.

Insulin sensitivity improves with testosterone normalization. Diabetic patients on insulin or sulfonylureas may need dose reductions 4 to 8 weeks after testosterone levels stabilize. The American Diabetes Association's 2023 Standards of Care note that low testosterone in men with type 2 diabetes is associated with insulin resistance [16].

Formulation Switching: Re-Titration Rules

When switching a stable patient from one formulation to another, treat it as a new initiation. Do not carry forward the optimized dose from the prior formulation. Start at the new formulation's approved starting dose, draw labs at steady state, and titrate from baseline.

The exception: switching between testosterone cypionate and enanthate at equivalent doses (1:1 mg conversion) rarely requires full re-titration, because pharmacokinetics are close enough that levels typically remain within range. Confirm with a trough draw at 6 weeks regardless.